Elicio Therapeutics, Inc. (ELTX)

4,1100 -2,7800 (-40,35%) Alla chiusura: 04:00PM EDT

Elicio Therapeutics, Inc.

451 D Street
5th Floor Suite 501
Boston, MA 02210
United States
857-209-0050
https://elicio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 32

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Robert T. Connelly	CEO, President & Director	612k	N/D	1960
Dr. Christopher M. Haqq M.D., Ph.D.	Executive VP, Head of Research & Development and Chief Medical Officer	589k	N/D	1966
Prof. Darrell J. Irvine Ph.D.	Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board	N/D	N/D	N/D
Mr. Brian Piekos	Chief Financial Officer	N/D	N/D	1975
Mr. Michael DiVecchia	Senior Vice President of Operations & Human Resources	N/D	N/D	N/D
Dr. Peter DeMuth Ph.D.	Chief Scientific Officer	N/D	N/D	1986
Ms. Megan C. Filoon	General Counsel, Secretary & Compliance Officer	N/D	N/D	N/D
Ms. Esther Welkowsky	Senior Vice President of Clinical Development	N/D	N/D	N/D
Ms. Joy Seymour	VP & Head of Regulatory Affairs	N/D	N/D	N/D
Dr. Thian Kheoh Ph.D.	Senior Vice President of Biometrics	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node–targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Elicio Therapeutics, Inc. al 1 giugno 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.